Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 32.43
0.123 %
$ 1.82 B
Market Cap
24.57
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Supernus Pharmaceuticals, Inc.
| Net Income | 73.9 M |
| Depreciation & Amortization | 80.4 M |
| Capital Expenditures | -725 K |
| Stock-Based Compensation | 27.8 M |
| Change in Working Capital | -2.05 M |
| Others | 7.18 M |
| Free Cash Flow | 171 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||||
| Net Income | 73.9 | 1.3 | 60.7 | 53.4 | 127.0 | 113.1 | 111.0 | 57.3 | 91.2 | 14.0 | 19.9 | (92.3) | (46.3) | (23.2) | (39.1) | 4.1 | (33.5) | (17.3) |
| Depreciation & Amortization | 80.4 | 84.9 | 85.5 | 32.6 | 18.1 | 6.7 | 7.1 | 8.1 | 2.4 | 0.9 | 0.9 | 0.7 | 0.9 | 0.9 | 1.2 | 1.1 | 1.1 | 0.9 |
| Deferred Income Tax | (20.1) | (25.7) | (26.3) | (5.0) | 0.6 | (5.8) | (4.2) | 21.2 | (41.8) | 2.1 | (0.4) | 23.0 | 0.7 | (16.2) | (0.4) | (4.6) | 0 | 0 |
| Stock Based Compensation | 27.8 | 26.8 | 17.6 | 17.9 | 16.6 | 14.8 | 11.3 | 8.4 | 5.9 | 4.2 | 2.7 | 1.9 | 0.4 | 82 K | 0.3 | 0.1 | 99 K | 74.1 K |
| Other Operating Activities | 12.1 | 33.0 | 3.6 | 24.6 | 12.7 | 13.8 | 8.5 | (4.1) | 0.6 | 0.7 | 2.1 | 3.0 | 0.3 | 2.3 | (0.4) | 0.4 | 0.2 | 0 |
| Change in Working Capital | (2.1) | (9.1) | (24.2) | 3.6 | (36.5) | 0.6 | (4.7) | 23.7 | 8.4 | 10.1 | (17.5) | 5.7 | (3.2) | 0.2 | 5.9 | 1.5 | 2.4 | 2.3 |
| Cash From Operations | 172.0 | 111.1 | 116.8 | 127.1 | 138.4 | 143.1 | 129.0 | 114.6 | 66.8 | 32.1 | 7.7 | (57.9) | (47.2) | (36.2) | (32.5) | 2.6 | (29.7) | (14.0) |
| INVESTING CASH FLOW | ||||||||||||||||||
| Capital Expenditures | (0.7) | (0.6) | (0.4) | (2.0) | (3.4) | (2.7) | (0.8) | (2.0) | (1.6) | (2.1) | (0.6) | (2.4) | (0.8) | (0.7) | (0.3) | (0.7) | (0.1) | (1.1) |
| Other Items | (189.1) | 269.3 | (216.3) | (79.9) | (31.2) | (155.2) | (412.6) | (84.4) | (34.4) | (34.1) | (4.3) | (9.8) | (48.2) | 34.6 | 26.1 | (27.7) | 15.6 | 15.9 |
| Cash From Investing Activities | (189.9) | 268.7 | (216.7) | (81.9) | (34.7) | (157.9) | (413.5) | (86.4) | (36.0) | (36.2) | (4.9) | (12.1) | (49.0) | 33.9 | 25.8 | (28.4) | 15.5 | 14.9 |
| FINANCING CASH FLOW | ||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | (402.5) | 0 | (137.5) | (0.8) | 0 | 309.6 | 0 | 0 | 0 | 0 | 65.7 | (6.8) | 30.0 | 0 | 0 | 75.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.7) | (2.0) | (22.9) | 0 | 0 | 0 | 55.3 | 0 | 0 | 0 | 1 K | (2.9) | (6.0) | (2.9) | (0.9) | 4.3 | (10.5) | 0 |
| Cash From Financing Activities | 12.2 | (397.9) | (10.5) | (130.4) | 3.6 | 3.9 | 376.4 | 5.7 | 2.1 | 1.9 | 0.6 | 62.7 | 87.9 | 27.1 | (0.9) | 4.3 | 64.5 | 5 K |
| CHANGE IN CASH | ||||||||||||||||||
| Net Change In Cash | (5.7) | (18.1) | (110.3) | (85.2) | 107.3 | (10.9) | 91.9 | 33.9 | 32.9 | (2.2) | 3.4 | (7.3) | (8.2) | 24.8 | (7.7) | (21.5) | 50.3 | 0.9 |
| FREE CASH FLOW | ||||||||||||||||||
| Free Cash Flow | 171.2 | 110.5 | 116.4 | 125.1 | 134.9 | 140.4 | 128.1 | 112.6 | 65.2 | 30.0 | 7.1 | (60.3) | (48.0) | (36.9) | (32.8) | 1.9 | (29.8) | (15.0) |